Antibody Conversion Services - Creative Biolabs

Online Inquiry

What is Antibody Conversion?

Looking to streamline your therapeutic antibody development and unlock its full potential? This comprehensive solution guide will provide you with a thorough understanding of antibody conversion, ensuring your products meet the highest standards of affinity, specificity, stability, and therapeutic efficacy. At Creative Biolabs, our comprehensive antibody conversion services are designed to support every stage of your research, helping you bring novel biologics to market with precision and efficiency.

"The humanization, caninization, and simianization services offered by Creative Biolabs have been a cornerstone of our biologics development. Each conversion was executed with precision, ensuring cross-species compatibility and functionality. "

- Andrew M. Director of Biologics Development

"Outstanding expertise in antibody engineering. The team's attention to detail and innovative approaches have significantly accelerated our development timeline."

- Sarah L. Senior Research Scientist

"Creative Biolabs' comprehensive platform and professional support have made them an invaluable partner in our antibody development projects."

- Michael R. Head of Immunotherapy Research

Antibody Conversion

Conversion	Subcategory	Description	Methods/Techniques	Challenges
Antibody Isotype Conversion	IgG, IgA, IgM, IgE conversion	Modifying antibody classes to adjust immune response	Recombinant DNA technology, site-directed mutagenesis	Structural changes affecting binding affinity and function
Antibody Species Conversion	Humanization (Convert to Human Ab)	Converting animal-derived antibodies into human or humanized antibodies to reduce immunogenicity	Premade human antibody library screening, FHAT transgenic mice, NHP antibody humanization, CDR grafting, backmatation	Affinity and specificity while minimizing immunogenicity
	Camelization (Convert to Single-Domain Ab)	Converting conventional antibodies into single-domain antibodies (sdAbs) for improved tissue penetration and stability	Phage display library screening, premade sdAb library screening, recombinant VHH expression	Preserving antigen specificity while minimizing size and maintaining stability
	Caninization (Convert to Dog Ab)	Adapting antibodies for use in canine models, preserving function and compatibility for veterinary applications	Canine-specific framework engineering, caninized phage display library screening	Balancing efficacy with species-specific immune compatibility
	Simianization (Convert to NHP Ab)	Converting antibodies into forms suitable for non-human primates (NHP)	Framework alignment with NHP sequences, CDR grafting, backmatation	Ensuring compatibility with primate immune systems while maintaining efficacy
	Murinization (Convert to Mouse Ab)	Modifying antibodies for expression and testing in murine models	Mouse-specific framework design, CDR grafting, phage display library screening	Retaining function while optimizing expression and avoiding immune rejection
	Felinization (Convert to Cat Ab)	Converting antibodies for feline models to enable diagnostics and therapeutics for cats	Cat-specific sequence modeling, framework adaptation	Preserving antibody integrity while ensuring immune compatibility in feline models
Fc Engineering	Fc region modification	Altering the Fc region to enhance effector functions	Protein engineering, Fc glycoengineering	Undesired immune response or altered clearance
ScFv/Fab Fragment Engineering	ScFv/Fab conversion	Enhancing scFv/Fab fragment specificity and binding	Converting full IgG/IgM into scFv/Fab, immunized phage display library, premade phage display scFv/Fab library,papain/pepsin digestion, recombinant expression	Balancing stability with binding efficiency, loss of stability and reduced half-life
Glycoengineering	Antibody glycosylation modification	Modifying glycan structures to enhance therapeutic properties	Glycosylation pathway engineering, glycosyltransferase enzymes	Controlling glycosylation patterns during production
ADC Conversion	Antibody-drug conjugate engineering	Converting antibodies for targeted drug delivery	Linker chemistry, click chemistry	Ensuring stable linker and specific payload release
Antibody-to-CAR Conversion	CAR-T and CAR-NK cell engineering	Converting antibodies into chimeric antigen receptors	Lentiviral transduction, CRISPR-Cas9 gene editing	Maintaining CAR functionality and minimizing off-target effects
PEGylation & Chemical Conjugation	PEGylated antibodies, fluorescent labeling	Chemically modifying antibodies for improved properties	PEGylation, bioconjugation	Preventing altered binding efficacy after chemical modifications
Antibody Reformatting for Delivery Systems	Liposome/EV-bound antibodies	Converting antibodies for encapsulation into delivery vehicles	Liposome encapsulation, electroporation	Achieving targeted delivery while maintaining functionality

What Types of Antibody Property Optimization Services Can We Provide for You?

We offer a comprehensive range of customizable antibody property optimization services to ensure that each antibody achieves the highest standards in terms of efficacy, stability, and safety, empowering your research with tailored solutions to accelerate development.

Technology Platform

Creative Biolabs is equipped with an extensive suite of cutting-edge technologies to support antibody conversion and optimization. Our platform integrates advanced tools such as phage and yeast display systems, high-throughput flow cytometry, for antibody screening and designs. We also utilize gene editing, lentiviral transduction systems, and molecular cloning techniques to streamline complex conversions, such as CAR-T antibody generation and bispecific antibody engineering. Additionally, we employ HPLC, SEC-MALS, LC-MS/MS, and surface plasmon resonance (SPR) for comprehensive characterization, ensuring that the converted antibodies meet the highest structural, functional, and stability criteria for therapeutic and diagnostic applications.

Service Advantages

Diverse Species and Format Conversion

Expertise in humanization, caninization, simianization, camelization, murinization, and felinization, along with seamless adaptation to bispecific, trispecific, sdAb, and ADC formats for versatile applications.

Precision and Structural Integrity Maintenance

Advanced engineering ensures binding affinity, specificity, and structural integrity are preserved throughout the conversion process for optimal performance.

Customizable Solutions Across Applications

Tailored services support therapeutic development, diagnostics, veterinary biologics, and research, meeting species- and format-specific needs with regulatory-compliant documentation.

End-to-End Project Support

From consultation to delivery, our experts provide comprehensive project management and technical assistance to meet all goals and timelines.

Comprehensive Validation and Compliance

Thorough validation services and precise documentation ensure alignment with regulatory standards for successful therapeutic development.

Fast Turnaround with Optimized Workflow

Accelerated processes and high-throughput capabilities enable clients to develop fast-track and hit key milestones efficiently.

With extensive expertise in antibody conversion, Creative Biolabs utilizes advanced platforms to provide high-quality, tailored solutions. Our reliable, cost-effective protocols empower global clients to accelerate their research and development of novel therapeutics and diagnostics.

Published Data

The Engineering of Human IgG3 Antibody to Reduce Aggregation

The human IgG3 subclass has the characteristics of high effect function and Fab arm flexibility. Here, the researchers used anti-CD20 IgG3 as a model to study the formation of IgG3 aggregates and the potential of such antibodies in treatment. The researchers swapped the constant domain of IgG3 with the constant domain of stable IgG1 to avoid a large number of aggregations of anti-CD20 IgG3 antibodies. The results showed that the collective formation of IgG3 antibodies with the IgG1 CH3 domain decreased. It was found that two amino acid mutations in the CH3 domain reduced the aggregation of IgG3 and increased the CH3 transition temperature. They improved the engineered human IgG3 antibody by further mutation and obtained IgG3KVH to achieve protein A binding and showed antigenic binding similar to that of wild-type IgG3. At the same time, IgG3KVH also has high binding activity to Fcγ RIIIa and C1q. In this study, the researchers obtained an engineered human IgG3 antibody with low aggregation, which will help to research and develop therapeutic antibodies with high effect function and Fab arm flexibility.

References

Saito, Seiji, et al. "A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress." Protein Science 28.5 (2019): 900-909. Distributed under Open Access license CC BY 4.0, without modification.

FAQs

What is antibody engineering?

Antibody engineering is a branch of biotechnology that involves the modification and synthesis of antibodies to enhance their effectiveness for specific applications. This can include altering the antibody's binding affinity, specificity, stability, or other pharmacological properties to make it more suitable for therapeutic use, diagnostic tools, or research purposes.

How are antibodies engineered?

There are several methods used to engineer antibodies, including phage display, where bacteriophages are used to evolve new antibodies; genetic engineering, where the DNA encoding antibodies is modified; and hybridoma technology, which involves fusing B-cells with immortal cells to produce monoclonal antibodies. Recent advancements also include the use of computational design and machine learning to predict and improve antibody structures.

What are the applications of engineered antibodies?

Engineered antibodies have a wide range of applications in medicine and research. In therapeutics, they are used as the basis for many antibody-drug conjugates, cancer immunotherapies, and treatments for autoimmune diseases. In diagnostics, engineered antibodies provide high specificity in tests for various diseases, including infectious diseases and cancer biomarkers.

How do antibody fragments fit into antibody engineering?

Antibody fragments such as Fab, F(ab')2, and single-chain variable fragments (scFv) play a crucial role in antibody engineering. These fragments retain the antigen-binding part of the antibody but lack the Fc region, which can be advantageous for reducing immunogenicity and improving tissue penetration. Engineering antibody fragments is particularly useful in therapeutic contexts where full-length antibodies might be too large or where non-essential parts of the antibody might trigger unwanted immune responses.

What role does computational biology play in antibody engineering?

Computational biology has become pivotal in antibody engineering, especially in predicting antibody structure, improving binding affinity, and identifying potential immunogenicity. Techniques such as molecular modeling, simulation, and machine learning algorithms can predict how mutations affect antibody behavior, guide the design of antibody libraries, and optimize antibodies for specific applications without the need for extensive in vitro testing.

Can engineered antibodies be used in all types of diseases?

Engineered antibodies are most prominently used in the treatment of cancers and autoimmune diseases due to their ability to be tailored to target specific pathological antigens. However, their use is expanding to infectious diseases, neurological disorders, and other conditions. The versatility of engineered antibodies lies in their ability to be customized for different targets and mechanisms, although their effectiveness can vary based on the nature of the disease and the target antigen's characteristics.

Related Resources

More Articles

Understanding Antibody Types and Their Structural Characteristics

Exploring Recombinant Antibodies: Formats and Generation Methods

Antibody Fragments: The Mighty Miniature Warriors Revolutionizing Biomedicine

Phage Display Technology as a Powerful Platform for Antibody Drug Discovery

Diagnostic Potential of Single Domain Antibody Produced by Camel